Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

332 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    Patentability Of Medical Use Inventions

    Jiancheng Jiang of Peksung asks whether a Higher Court judgment in favour of a medical use claim brings new hope for inventors.
    ChinaIntellectual Property
    Wan Hui Da - Peksung IP Group
    Wan Hui Da - Peksung IP Group
  • Article

    Grounds, Procedure And Timeline For Filing An Administrative Complaint Regarding False Advertising In China

    In January 2022, Estee Lauder (China), the international beauty and skincare company, was fined RMB 2,381,671 (approximately USD 350,000) for false advertising in China.
    ChinaMedia, Telecoms, IT, Entertainment
    Gowling WLG
    Gowling WLG
Article

Navigating The Latest Challenges Of China's Human Genetic Resources Regulation

Multinational pharmaceutical and medical device companies conducting clinical trials in China have been facing new challenges in the year since the Regulation on Human Genetic Resources...
ChinaFood, Drugs, Healthcare, Life Sciences
Arnold & Porter
Arnold & Porter
  • Article

    中医薬基盤モデル「デジタル・スマート本草」が天津で発表

    天津で今月9日に開催された「デジタル・スマートでエンパワーメン...
    ChinaFood, Drugs, Healthcare, Life Sciences
    Kangxin
    Kangxin
  • Article

    IP Boosts Bio-Economy Development In China

    Bio-economy is a new economy based on the development, progress and popularization of life science and biotechnologies, as well as an integral part of the national economy.
    ChinaIntellectual Property
    AFD China
    AFD China
  • Article

    Patent Protection Of Gene Mutants In China

    With the development of biotechnology, a variety of enzymes have been used in industrial production, such as enzyme-catalyzed synthesis of compounds, especially chiral drugs...
    ChinaIntellectual Property
    Kangxin
    Kangxin
  • Article

    China Addresses the Problem of Fake Food

    In the last edition of this update, we featured the Hong Kong Government's public consultation on a nutrition labelling scheme for pre-packaged foods. Since that article a disturbing related issue has emerged in Hong Kong and mainland China. Most people are familiar with the trade in counterfeit items all over the world such as watches, computer games, DVDs and clothing. Whilst this is a major concern for multi-national and local companies who wish to protect their intellectual property righ
    ChinaEnergy and Natural Resources
    Lovells
    Lovells
  • Article

    China's New Draft Administrative Measures For Management Of Medical Representatives

    On November 28, 2024, China's National Medical Products Administration (NMPA, 国家药品监督管理局), China's equivalent of the U.S. Food and Drug Administration...
    ChinaFood, Drugs, Healthcare, Life Sciences
    Arnold & Porter
    Arnold & Porter
  • Article

    China's New Regulatory Data Protection Regime Becomes Effective Immediately

    China's National Medical Products Administration has introduced a groundbreaking regulatory data protection framework that grants up to six years of clinical data exclusivity for pharmaceuticals.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    The New Draft Administrative Measures For Management Of Medical Representatives

    On November 28, 2024, China's National Medical Products Administration (NMPA, 国家药品监督管理局), China's equivalent of the U.S. Food and Drug Administration,
    ChinaFood, Drugs, Healthcare, Life Sciences
    Arnold & Porter
    Arnold & Porter
  • Article

    中国が完全な独自の知的財産権を持つ「人工心臓」が臨床試験段階へ

    泰達国際心血管疾患病院(以下「同病院」)...
    ChinaFood, Drugs, Healthcare, Life Sciences
    Kangxin
    Kangxin
  • Article

    ライブ販売の商標侵害に厳罰 山東高裁、懲罰的賠償で抑止強化

    山東省高級人民法院(高裁)はこのほど、2025年の知的財産分野における懲罰的賠償の典型事例を公表した...
    ChinaIntellectual Property
    Kangxin
    Kangxin
  • Article

    CFDA Amends Medical Device Recall Rules

    Recently China's Food and Drug Administration ("CFDA") released the Provisions for Medical Device Recall ("New Recall Rules").
    ChinaConsumer Protection
    Ropes & Gray LLP
    Ropes & Gray LLP
  • Article

    Highlights On The Draft HGR Regulations Implementing Rules

    China began legislating the protection of human genetic resources in 1998, at which time the Ministry of Science and Technology (MOST) and the Ministry of Health jointly formulated...
    ChinaFood, Drugs, Healthcare, Life Sciences
    Han Kun Law Offices
    Han Kun Law Offices
  • Article

    Relaxation Of Long-Standing Restrictions On Foreign Investment In The Healthcare Sector In China

    The demand for medical services in China is growing, with the country's ageing population set against its potential for economic development.
    ChinaFood, Drugs, Healthcare, Life Sciences
    McDermott Will & Emery
    McDermott Will & Emery
  • Article

    Feasible Way To Define A New Protein Patent And Subsequently Obtained Scope Of Protection Novo Nordisk Vs. Longda Co.,Ltd. And Boli Co.,Ltd. (Article No. 24 From "China Patent Case Review 2015" By Beijing East IP Ltd.)

    The patentee Novo Nordisk from Denmark possesses an invention patent titled "Thermostable Glucoamylase" with the patent number No. ZL98813338.5.
    ChinaIntellectual Property
    Beijing East IP Law Firm
    Beijing East IP Law Firm
  • Article

    "Biological Safety Is Part Of The National Security" – Introduction To China's Draft Biological Safety Law (Part I)

    On 30 April 2020, the National People's Congress of China (the "NPC") published the Biological Safety Law (Draft for Second Reading) (the "Draft Law") for public consultation until 13 June 20201.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Mayer Brown
    Mayer Brown
  • Article

    China's Ministry Of Science And Technology Publishes Draft Rules On The Administration Of Human Genetic Resources

    China's Ministry of Science and Technology (MOST) issued the Draft Implementing Rules on the Administrative Regulations on Human Genetic Resources for public comment (the "Draft Implementing Rules") on March 22, 2022.
    ChinaFood, Drugs, Healthcare, Life Sciences
    Ropes & Gray LLP
    Ropes & Gray LLP
  • Article

    China's New Medical Device Regulations Bring Big Changes

    The current MDR requires medtech companies to either conduct clinical studies in China or submit clinical evaluation reports illustrating equivalence to previously approved products
    ChinaFood, Drugs, Healthcare, Life Sciences
    Ropes & Gray LLP
    Ropes & Gray LLP
  • Article

    Upcoming CFDA Inspection On Class I And Class II Medical Devices Manufacturers

    Circular (2014) No.15 provides for the specific deadlines for different domestic medical devices manufacturing companies to gradually meet the Medical Devices Manufacturing Quality Management Standards
    ChinaFood, Drugs, Healthcare, Life Sciences
    CMS Cameron McKenna Nabarro Olswang
    CMS Cameron McKenna Nabarro Olswang
  • Showing 101–120 of 332 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics